Definitions, End Points, and Clinical Trial Designs for Bladder Cancer: Recommendations From the Society for Immunotherapy of Cancer and the International Bladder Cancer Group

被引：26

作者：

Kamat, Ashish M. ^{[1
,25
]}

Apolo, Andrea B. ^{[2
]}

Babjuk, Marek ^{[3
]}

Bivalacqua, Trinity J. ^{[4
]}

Black, Peter C. ^{[5
]}

Buckley, Roger ^{[6
]}

Campbell, Matthew T. ^{[7
]}

Comperat, Eva ^{[8
]}

Efstathiou, Jason A. ^{[9
]}

Grivas, Petros ^{[10
,11
]}

Gupta, Shilpa ^{[12
]}

Kurtz, Neil J. ^{[13
]}

Lamm, Donald ^{[14
]}

Lerner, Seth P. ^{[15
]}

Li, Roger ^{[16
]}

Mcconkey, David J. ^{[17
]}

Redorta, Joan Palou ^{[16
]}

Powles, Thomas ^{[18
]}

Psutka, Sarah P. ^{[19
]}

Shore, Neal ^{[20
]}

Steinberg, Gary D. ^{[21
]}

Sylvester, Richard ^{[22
]}

Witjes, J. Alfred ^{[23
]}

Galsky, Matthew D. ^{[24
]}

机构：

[1] Univ Texas MD Anderson Canc Ctr, Dept Urol, Houston, TX USA

[2] NCI, Ctr Canc Res, NIH, Bethesda, MD USA

[3] Charles Univ Prague, Teaching Hosp Motol, Fac Med 2, Dept Urol, Prague, Czech Republic

[4] Univ Penn, Dept Surg, Div Urol, Philadelphia, PA USA

[5] Univ British Columbia, Dept Urol Sci, Vancouver, BC, Canada

[6] North York Gen Hosp, Dept Urol, Toronto, ON, Canada

[7] Univ Texas MD Anderson Canc Ctr, Dept Genitourinary Med Oncol, Div Canc Med, Houston, TX USA

[8] Med Univ Vienna, Dept Pathol, Vienna, Austria

[9] Harvard Med Sch, Massachusetts Gen Hosp, Dept Radiat Oncol, Boston, MA USA

[10] Univ Washington, Dept Med, Div Oncol, Seattle, WA USA

[11] Fred Hutchinson Canc Ctr, Clin Res Div, Seattle, WA USA

[12] Taussig Canc Inst, Dept Hematol & Med Oncol, Cleveland Clin, Cleveland, OH USA

[13] Bladder Canc Advocacy Network BCAN, Patient Advocate, Bethesda, MD USA

[14] BCG Oncol, Phoenix, AZ USA

[15] Baylor Coll Med, Dan Duncan Canc Ctr, Scott Dept Urol, Houston, TX USA

[16] H Lee Moffitt Canc Ctr & Res Inst, Dept Genitourinary Oncol, Tampa, FL USA

[17] Johns Hopkins Univ, Johns Hopkins Greenberg Bladder Canc Inst, Baltimore, MD USA

[18] Queen Mary Univ London, London, England

[19] Univ Washington, Fred Hutchinson Canc Ctr, Dept Urol, Seattle, WA USA

[20] Carolina Urol Res Ctr, Myrtle Beach, SC USA

[21] Rush Univ, Med Ctr, Dept Urol, Chicago, IL USA

[22] EAU NMIBC Guidelines Panel, Arnhem, Netherlands

[23] Radboud Univ Nijmegen, Med Ctr, Nijmegen, Netherlands

[24] Tisch Canc Inst, Icahn Sch Med Mt Sinai, New York, NY USA

[25] Univ Texas MD Anderson Canc Ctr, Dept Urol, 1155 Pressler St,Unit 1373,CBP7 3269, Houston, TX 77030 USA

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷 / 35期

关键词：

CARCINOMA IN-SITU; SEQUENTIAL INTRAVESICAL GEMCITABINE; UROTHELIAL CARCINOMA; NEOADJUVANT CHEMOTHERAPY; RADICAL CYSTECTOMY; TUMOR MARKERS; CISPLATIN; EFFICACY; DOCETAXEL; DIAGNOSIS;

D O I：

10.1200/JCO.23.00307

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

PURPOSEThere is a significant unmet need for new and efficacious therapies in urothelial cancer (UC). To provide recommendations on appropriate clinical trial designs across disease settings in UC, the Society for Immunotherapy of Cancer (SITC) and the International Bladder Cancer Group (IBCG) convened a multidisciplinary, international consensus panel.METHODSThrough open communication and scientific debate in small- and whole-group settings, surveying, and responses to clinical questionnaires, the consensus panel developed recommendations on optimal definitions of the disease state, end points, trial design, evaluations, sample size calculations, and pathology considerations for definitive studies in low- and intermediate-risk nonmuscle-invasive bladder cancer (NMIBC), high-risk NMIBC, muscle-invasive bladder cancer in the neoadjuvant and adjuvant settings, and metastatic UC. The expert panel also solicited input on the recommendations through presentations and public discussion during an open session at the 2021 Bladder Cancer Advocacy Network (BCAN) Think Tank (held virtually).RESULTSThe consensus panel developed a set of stage-specific bladder cancer clinical trial design recommendations, which are summarized in the table that accompanies this text.CONCLUSIONThese recommendations developed by the SITC-IBCG Bladder Cancer Clinical Trial Design consensus panel will encourage uniformity among studies and facilitate drug development in this disease.

引用

页码：5437 / +

页数：13

共 54 条

[1] What to do during Bacillus Calmette-Guerin shortage? Valid strategies based on evidence [J].

Abufaraj, Mohammad ;

Mostafid, Hugh ;

Shariat, Shahrokh F. ;

Babjuk, Marek .

CURRENT OPINION IN UROLOGY, 2018, 28 (06) :570-576

[2] Eligibility and Radiologic Assessment in Adjuvant Clinical Trials in Bladder Cancer [J].

Apolo, Andrea B. ;

Milowsky, Matthew I. ;

Kim, Lauren ;

Inman, Brant A. ;

Kamat, Ashish M. ;

Steinberg, Gary ;

Bagheri, Mohammadhadi ;

Krishnasamy, Venkatesh P. ;

Marko, Jamie ;

Dinney, Colin P. ;

Bangs, Rick ;

Sweis, Randy F. ;

Maher, Virginia Ellen ;

Ibrahim, Amna ;

Liu, Ke ;

Werntz, Ryan ;

Cross, Frank ;

Beaver, Julia A. ;

Singh, Harpreet ;

Pazdur, Richard ;

Blumenthal, Gideon M. ;

Lerner, Seth P. ;

Bajorin, Dean F. ;

Rosenberg, Jonathan E. ;

Agrawal, Sundeep .

JAMA ONCOLOGY, 2019, 5 (12) :1790-1798

[3] Clinical Value of Fluorine-18 2-Fluoro-2-Deoxy-D-Glucose Positron Emission Tomography/Computed Tomography in Bladder Cancer [J].

Apolo, Andrea B. ;

Riches, Jamie ;

Schoeder, Heiko ;

Akin, Oguz ;

Trout, Alisa ;

Milowsky, Matthew I. ;

Bajorin, Dean F. .

JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (25) :3973-3978

[4] Adjuvant Nivolumab versus Placebo in Muscle-Invasive Urothelial Carcinoma [J].

Bajorin, D. F. ;

Witjes, J. A. ;

Gschwend, J. E. ;

Schenker, M. ;

Valderrama, B. P. ;

Tomita, Y. ;

Bamias, A. ;

Lebret, T. ;

Shariat, S. F. ;

Park, S. H. ;

Ye, D. ;

Agerbaek, M. ;

Enting, D. ;

McDermott, R. ;

Gajate, P. ;

Peer, A. ;

Milowsky, M., I ;

Nosov, A. ;

Antonio Jr, J. N. ;

Tupikowski, K. ;

Toms, L. ;

Fischer, B. S. ;

Qureshi, A. ;

Collette, S. ;

Unsal-Kacmaz, K. ;

Broughton, E. ;

Zardavas, D. ;

Koon, H. B. ;

Galsky, M. D. .

NEW ENGLAND JOURNAL OF MEDICINE, 2021, 384 (22) :2102-2114

[5] Impact of 18 FDG- PET CT in the Management of Muscle Invasive Bladder Cancer [J].

Bertolaso, Pauline ;

Brouste, Veronique ;

Cazeau, Anne-Laure ;

de Clermont-Gallerande, Henri ;

Bladou, Franck ;

Cabart, Mathilde ;

Lefort, Felix ;

Gross-Goupil, Marine .

CLINICAL GENITOURINARY CANCER, 2022, 20 (03) :297-297.e6

[6] Treatment of Non-Metastatic Muscle-Invasive Bladder Cancer: AUA/ASCO/ASTRO/SUO Guideline [J].

Chang, Sam S. ;

Bochner, Bernard H. ;

Chou, Roger ;

Dreicer, Robert ;

Kamat, Ashish M. ;

Lerner, Seth P. ;

Lotan, Yair ;

Meeks, Joshua J. ;

Michalski, Jeff M. ;

Morgan, Todd M. ;

Quale, Diane Z. ;

Rosenberg, Jonathan E. ;

Zietman, Anthony L. ;

Holzbeierlein, Jeffrey M. .

JOURNAL OF UROLOGY, 2017, 198 (03) :552-559

[7] Diagnosis and Treatment of Non-Muscle Invasive Bladder Cancer: AUA/SUO Guideline [J].

Chang, Sam S. ;

Boorjian, Stephen A. ;

Chou, Roger ;

Clark, Peter E. ;

Daneshmand, Siamak ;

Konety, Badrinath R. ;

Pruthi, Raj ;

Quale, Diane Z. ;

Ritch, Chad R. ;

Seigne, John D. ;

Skinner, Eila Curlee ;

Smith, Norm D. ;

McKiernan, James M. .

JOURNAL OF UROLOGY, 2016, 196 (04) :1021-1029

[8] Liquid Biopsy Analysis of FGFR3 and PIK3CA Hotspot Mutations for Disease Surveillance in Bladder Cancer [J].

Christensen, Emil ;

Birkenkamp-Demtroder, Karin ;

Nordentoft, Iver ;

Hoyer, Soren ;

van der Keur, Kirstin ;

van Kessel, Kim ;

Zwarthoff, Ellen ;

Agerbaek, Mads ;

Orntoft, Torben Falck ;

Jensen, Jorgen Bjerggaard ;

Dyrskjot, Lars .

EUROPEAN UROLOGY, 2017, 71 (06) :961-969

[9] Safety and Efficacy of Immune Checkpoint Inhibitor Therapy in Patients With HIV Infection and Advanced-Stage Cancer A Systematic Review [J].

Cook, Michael R. ;

Kim, Chul .

JAMA ONCOLOGY, 2019, 5 (07) :1049-1054

[10] Hexaminolevulinate blue-light cystoscopy in non-muscle-invasive bladder cancer: review of the clinical evidence and consensus statement on appropriate use in the USA [J].

Daneshmand, Siamak ;

Schuckman, Anne K. ;

Bochner, Bernard H. ;

Cookson, Michael S. ;

Downs, Tracy M. ;

Gomella, Leonard G. ;

Grossman, H. Barton ;

Kamat, Ashish M. ;

Konety, Badrinath R. ;

Lee, Cheryl T. ;

Pohar, KamalS. ;

Pruthi, Raj S. ;

Resnick, Matthew J. ;

Smith, Norm D. ;

Witjes, J. Alfred ;

Schoenberg, Mark P. ;

Steinberg, Gary D. .

NATURE REVIEWS UROLOGY, 2014, 11 (10) :589-596

← 1 2 3 4 5 6 →